34.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Precedente Chiudi:
$33.37
Aprire:
$33.09
Volume 24 ore:
2.97M
Relative Volume:
1.00
Capitalizzazione di mercato:
$6.50B
Reddito:
$217.77M
Utile/perdita netta:
$-438.86M
Rapporto P/E:
-14.21
EPS:
-2.41
Flusso di cassa netto:
$-456.33M
1 W Prestazione:
+2.73%
1M Prestazione:
-5.96%
6M Prestazione:
+26.43%
1 anno Prestazione:
+18.72%
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Nome
Bridgebio Pharma Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Confronta BBIO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BBIO
Bridgebio Pharma Inc
|
34.25 | 6.33B | 217.77M | -438.86M | -456.33M | -2.41 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-31 | Iniziato | Redburn Atlantic | Buy |
2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
2024-10-03 | Iniziato | Oppenheimer | Perform |
2024-09-04 | Iniziato | Piper Sandler | Overweight |
2024-03-21 | Ripresa | Raymond James | Outperform |
2024-01-31 | Iniziato | BMO Capital Markets | Market Perform |
2023-12-08 | Iniziato | Wells Fargo | Overweight |
2023-11-07 | Iniziato | Citigroup | Buy |
2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
2023-07-18 | Downgrade | Jefferies | Buy → Hold |
2023-04-19 | Iniziato | Evercore ISI | Outperform |
2023-02-06 | Iniziato | Cowen | Outperform |
2021-12-27 | Reiterato | Mizuho | Buy |
2021-12-27 | Reiterato | SVB Leerink | Outperform |
2021-09-10 | Aggiornamento | BofA Securities | Neutral → Buy |
2021-05-21 | Iniziato | UBS | Buy |
2021-03-22 | Reiterato | Goldman | Buy |
2021-02-22 | Ripresa | JP Morgan | Overweight |
2021-02-09 | Ripresa | Goldman | Buy |
2021-01-11 | Reiterato | H.C. Wainwright | Buy |
2020-12-10 | Reiterato | H.C. Wainwright | Buy |
2020-06-25 | Iniziato | BofA/Merrill | Neutral |
2020-05-19 | Iniziato | BTIG Research | Buy |
2020-04-13 | Iniziato | H.C. Wainwright | Buy |
2020-02-19 | Iniziato | Mizuho | Buy |
2019-07-26 | Iniziato | Raymond James | Outperform |
2019-07-22 | Iniziato | BMO Capital Markets | Outperform |
2019-07-22 | Iniziato | Goldman | Buy |
2019-07-22 | Iniziato | JP Morgan | Overweight |
2019-07-22 | Iniziato | Jefferies | Buy |
2019-07-22 | Iniziato | Piper Jaffray | Overweight |
2019-07-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st
BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria
Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com
Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha
BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey
Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com
BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus
Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan
BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria
BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis - marketscreener.com
BridgeBio’s acoramidis shows promise in ATTR-CM study - Investing.com
BridgeBio Pharma Reports Positive Phase 3 Results for Acoramidis, Highlighting Improved Survival Rates in ATTR-CM Patients - Nasdaq
Breakthrough ATTR-CM Study: Higher TTR Levels from Acoramidis Directly Predict 31% Better Survival Rates - Stock Titan
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study - Yahoo Finance
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade - MSN
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - Yahoo
Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday - Yahoo Finance
Fibroblast Growth Factors (FGFs) Market reached US$ 303.75 - openPR.com
Massive Sell-Offs Just Hit These 10 Stocks Today - Insider Monkey
BridgeBio (BBIO) Begins Dosing in ACT-EARLY Trial with Acoramidis | BBIO Stock News - GuruFocus
BridgeBio launches landmark ATTR prevention study - Investing.com Australia
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - The Manila Times
BridgeBio launches landmark ATTR prevention study By Investing.com - Investing.com Nigeria
BridgeBio to Present Clinical Outcomes, Quality of Life Measures - GuruFocus
BridgeBio Pharma to Present Key Findings on Acoramidis at Heart Failure Association Congress 2025 - Nasdaq
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC - The Manila Times
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
(BBIO) Trading Report - news.stocktradersdaily.com
Raymond James Financial Inc. Invests $456,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - The Manila Times
Recursion cuts nearly half of its pipeline - statnews.com
Achondroplasia Market: Epidemiology, Therapies, Companies, - openPR.com
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating - marketscreener.com
Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO Stock News - GuruFocus
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - ADVFN
BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO St - GuruFocus
BridgeBio Pharma Stock (BBIO) Jumps on Strong Drug Launch - The Globe and Mail
Cantor Fitzgerald Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q1 2025 Earnings Call Transcript - Insider Monkey
High Growth Tech Stocks In The US Market May 2025 - simplywall.st
BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Excellent Earnings Propelled Prices of These 10 Firms - Insider Monkey
Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):